Skip to main
ABVX

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 58%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Abivax is positioned for success with its first-in-class oral therapy for inflammatory bowel diseases, obefazimod, which has demonstrated best-in-disease efficacy in Phase 2 trials. With a favorable safety profile and promising data from Phase 3 trials, the company is on track for potential approval in 2026. Upside optionality in combination therapy, Crohn's Disease, and potential in other indications only add to the positive outlook for this biotech company.

Bears say

Abivax is a company focused on developing therapeutics for chronic inflammatory diseases. However, its sales and earnings potential are limited due to its single operating segment and early-stage drug development. There may also be market skepticism over the effectiveness and safety of obefazimod, as demonstrated by the high dropout rates in clinical trials, and potential competition from established treatments for inflammatory bowel diseases.

Abivax SA (ABVX) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 58% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 12 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $152.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $152.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.